FDA Approves Durvalumab Plus BCG to Cut Bladder Cancer Recurrence Risk by 32%
AstraZeneca's IMFINZI combined with BCG therapy wins FDA approval, slashing high-risk bladder cancer recurrence risk by nearly a third.
Summary
The FDA has approved durvalumab (IMFINZI) combined with BCG therapy for adults with high-risk, non-muscle-invasive bladder cancer who have not previously received BCG. The decision follows the Phase III POTOMAC trial, which showed adding one year of durvalumab to standard BCG reduced the risk of disease recurrence, progression, or death by 32% compared to BCG alone. With over five years of follow-up, the benefit appeared early and was sustained, and median disease-free survival had not yet been reached. Safety profiles were consistent with known risks, quality of life was preserved, and patients were still able to complete their BCG course — a meaningful outcome for over 31,000 Americans treated annually for this condition.
Detailed Summary
Bladder cancer is among the most common cancers worldwide, and the non-muscle-invasive form — while often treatable — carries a significant risk of recurrence and progression to more dangerous stages. Standard treatment with BCG (Bacillus Calmette-Guérin), a decades-old immunotherapy, leaves many patients vulnerable to disease return. The FDA's new approval addresses this gap directly.
AstraZeneca's immunotherapy durvalumab (IMFINZI), an immune checkpoint inhibitor targeting PD-L1, has now been approved in combination with BCG induction and maintenance therapy for BCG-naïve, high-risk non-muscle-invasive bladder cancer. The approval is based on the POTOMAC Phase III randomized trial, which demonstrated a 32% reduction in the composite risk of recurrence, progression, or death (hazard ratio 0.68; 95% CI 0.50–0.93; P=0.0154) when durvalumab was added for one year.
With a median follow-up of 60.7 months — nearly five years — the disease-free survival benefit emerged early and remained durable. Crucially, the median disease-free survival had not yet been reached in the durvalumab arm, suggesting the long-term advantage may be even greater than current data reflect.
Safety results were reassuring. The combination did not introduce new safety signals, did not impair patients' ability to complete BCG therapy, and had no meaningful negative impact on patient-reported quality of life — factors that matter greatly for treatment adherence and wellbeing during therapy.
For longevity-focused readers, this approval is relevant as a disease prevention milestone: catching and controlling bladder cancer earlier reduces the cascade of aggressive treatments, systemic inflammation, and physiological stress that can accelerate biological aging. Regulatory reviews are ongoing in the EU, Japan, and other countries. Those at elevated bladder cancer risk — including older adults and long-term smokers — should discuss evolving treatment options with their urologist.
Key Findings
- Durvalumab plus BCG reduced bladder cancer recurrence, progression, or death risk by 32% vs BCG alone.
- Disease-free survival benefit appeared early and persisted over nearly 5 years of follow-up.
- Median disease-free survival had not yet been reached, suggesting continued long-term benefit.
- Safety profile was clean — no new signals, BCG completion rates preserved, quality of life maintained.
- Over 31,000 Americans per year are treated for high-risk non-muscle-invasive bladder cancer, broadening impact.
Methodology
This is a news report summarizing a corporate press release and FDA approval announcement based on the Phase III POTOMAC randomized controlled trial. The source, Longevity.Technology, is a credible health and longevity media outlet. Evidence quality is high given the Phase III RCT basis, though full peer-reviewed publication data should be consulted for deeper analysis.
Study Limitations
Data derives from a company press release rather than a full peer-reviewed publication; independent validation of all reported outcomes is advisable. Long-term survival data beyond 5 years and cost-effectiveness analyses are not yet available. Approval is currently US-only; EU and Japan reviews are still pending.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.